

Application Serial No. 09/730,663 (Attorney Docket No. 3405/0/US)
Amendment dated March 14, 2005
Reply to Office action dated December 13, 2004

bioavailability (e.g., shorter time to reach a threshold therapeutic concentration in blood plasma, greater C_{max} and/or shorter T_{max}) as measured in a standard *in vivo* pharmacokinetic study, compared with an otherwise similar celecoxib drug substance wherein all, or a substantial portion of, the celecoxib is crystalline."

Conclusion

The Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,



Patricia K. Fitzsimmons
Registration No. 52,894

Pharmacia Corporation
Post Office Box 1027
St. Louis, MO 63006
Telephone: 314.274.1490
Facsimile: 314.274.9095

Enclosures:

Amendment Transmittal
Transmittal Letter
Itemized Postcard